Figure 3
(A) TP53 mutation is associated with poorer survival in CLL. Overall survival from the time point of diagnosis of the cohort of CLL patients according to absence or presence of TP53 mutation (n = 125; P < .002). (B) TP53 mutation is associated with poorer survival in CLL. Overall survival of the cohort of CLL patients according to absence or presence of TP53 mutation from the time of mutation analysis (n = 125; P < .001). (C) TP53 mutation without 17p deletion, 17p deletion without TP53 mutation, and the combination of TP53 mutation plus 17p deletion are all associated with poor survival in CLL. Overall survival of the cohort of CLL patients according to absence or presence of TP53 mutation/17p deletion from the time of mutation analysis (n = 125; P < .001).

(A) TP53 mutation is associated with poorer survival in CLL. Overall survival from the time point of diagnosis of the cohort of CLL patients according to absence or presence of TP53 mutation (n = 125; P < .002). (B) TP53 mutation is associated with poorer survival in CLL. Overall survival of the cohort of CLL patients according to absence or presence of TP53 mutation from the time of mutation analysis (n = 125; P < .001). (C) TP53 mutation without 17p deletion, 17p deletion without TP53 mutation, and the combination of TP53 mutation plus 17p deletion are all associated with poor survival in CLL. Overall survival of the cohort of CLL patients according to absence or presence of TP53 mutation/17p deletion from the time of mutation analysis (n = 125; P < .001).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal